Mallinckrodt Pharmaceuticals a leading global specialty biopharmaceutical company, will present on Tuesday, May 24, 2016, at the UBS Global Healthcare Conference at the Grand Hyatt New York, 109 E. 42nd St., New York.
World pharma today/News/-Matthew Harbaugh, Senior Vice President and Chief Financial Officer, and Cole Lannum, Senior Vice President of Investor Strategy and Investor Relations Officer, will represent the company in a fireside chat session at 2:30 p.m. Eastern time.
Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and therapies, as well as nuclear imaging products. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; analgesics and hemostasis products; and central nervous system drugs. The company's core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines; its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the Nuclear Imaging segment includes nuclear imaging agents. To learn more about Mallinckrodt, visit www.mallinckrodt.com
Investor RelationsColeman N. Lannum, CFA
Senior Vice President, Investor Strategy and IRO
Senior Manager, Communications
Senior Vice President, Communications and Publc